H
Hainan Shuangcheng Pharmaceuticals
Specialized manufacturer of synthetic peptide API and drugs
About Hainan Shuangcheng Pharmaceuticals
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (HNSP) is a publicly-traded pharmaceutical company specializing in the research, development, manufacturing, and marketing of chemically synthesized peptide drugs. Founded on May 22, 2000, the company has established itself as a high-tech enterprise with a comprehensive technology system for peptide drug synthesis, purification, and formulation. The company's legal representative is Wang Chengdong. HNSP was listed on the Shenzhen Stock Exchange on August 8, 2012.
The company's business model is centered on the production and sale of both Active Pharmaceutical Ingredients (APIs) and finished drug products to a global market, with sales in North America, Europe, and the Middle East. It also provides Contract Development and Manufacturing Organization (CDMO) services. The firm's product portfolio includes treatments for liver disease, cancer, and infectious diseases. Key products include Thymalfasin for injection (brand name "Jitai") for immune enhancement, Somatostatin for injection, and Bivalirudin for injection, which has received FDA approval. Several of its products and facilities are approved by international regulatory bodies, including the U.S. FDA and the Italian Medicines Agency (AIFA).
Headquartered in Haikou, Hainan Province, China, the company operates R&D and manufacturing facilities at its Haikou site and is expanding with new facilities in Ningbo. It also has a subsidiary in Italy, reflecting its strategy to become a leading global supplier of peptide APIs and a major producer of generic peptide drug formulations. The company's distribution network covers over 30 provinces in China, with more than 600 partner medical businesses and product coverage in over 10,000 hospitals.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2012
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Hainan Shuangcheng Pharmaceuticals in the Haikou ecosystem
The Hainan Shuangcheng Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hainan Shuangcheng Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hainan Shuangcheng Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
